company background image
OPGN

OpGenNasdaqCM:OPGN Stock Report

Market Cap

US$60.0m

7D

2.0%

1Y

-22.6%

Updated

30 Nov, 2021

Data

Company Financials +
OPGN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

OPGN Stock Overview

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally.

OpGen Competitors

T2 Biosystems

NasdaqGM:TTOO

US$104.0m

Roche Holding

SWX:ROG

CHF309.5b

Thermo Fisher Scientific

NYSE:TMO

US$251.7b

Danaher

NYSE:DHR

US$233.3b

Price History & Performance

Summary of all time highs, changes and price drops for OpGen
Historical stock prices
Current Share PriceUS$1.54
52 Week HighUS$4.37
52 Week LowUS$1.43
Beta-0.74
1 Month Change-13.97%
3 Month Change-51.88%
1 Year Change-22.61%
3 Year Change-92.97%
5 Year Change-99.74%
Change since IPO-99.94%

Recent News & Updates

Jun 15

OpGen gains on insider buying

Makhbubakhon Ismatova/iStock via Getty Images The precision medicine company OpGen ([[OPGN]] +4.2%) appears to be on track to end its three-day losing streak after the company revealed insider transactions by its chief executive officer Oliver Schacht and chief operating officer Johannes Bacher. Per the SEC filings submitted yesterday, Schacht and Bacher have bought ~$44.7K and ~$44.8K worth of shares, respectively in a series of transactions dated June 10. As the pandemic impact on the global economy wanes, “we believe our balanced product portfolio

Jun 07

OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates

OpGen (OPGN) has submitted an updated 510(k) summary document to the FDA for its Acuitas AMR Gene Panel for Isolates.This document incorporates all of the FDA’s requested updates to various key documents such as the Package Insert, Electronic User Guide, and Operator Manual. Consistent with the Agency's previously communicated timeline, the FDA provided substantive feedback on all of these key documents by the end of May.The FDA previously informed OpGen that it intends to complete its review by the end

Shareholder Returns

OPGNUS BiotechsUS Market
7D2.0%2.0%-0.9%
1Y-22.6%4.9%23.3%

Return vs Industry: OPGN underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: OPGN underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is OPGN's price volatile compared to industry and market?
OPGN volatility
OPGN Average Weekly Movement10.7%
Biotechs Industry Average Movement8.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: OPGN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: OPGN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2001102Oliver Schachthttps://www.opgen.com

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

OpGen Fundamentals Summary

How do OpGen's earnings and revenue compare to its market cap?
OPGN fundamental statistics
Market CapUS$59.98m
Earnings (TTM)-US$35.10m
Revenue (TTM)US$4.23m

14.2x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OPGN income statement (TTM)
RevenueUS$4.23m
Cost of RevenueUS$13.04m
Gross Profit-US$8.81m
ExpensesUS$26.29m
Earnings-US$35.10m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.90
Gross Margin-208.16%
Net Profit Margin-829.33%
Debt/Equity Ratio63.5%

How did OPGN perform over the long term?

See historical performance and comparison

Valuation

Is OpGen undervalued compared to its fair value and its price relative to the market?

1.8x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OPGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OPGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OPGN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: OPGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OPGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OPGN is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is OpGen forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

17.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPGN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OPGN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OPGN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OPGN's revenue (76.7% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: OPGN's revenue (76.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OPGN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has OpGen performed over the past 5 years?

-14.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OPGN is currently unprofitable.

Growing Profit Margin: OPGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OPGN is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.

Accelerating Growth: Unable to compare OPGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: OPGN has a negative Return on Equity (-105.42%), as it is currently unprofitable.


Financial Health

How is OpGen's financial position?


Financial Position Analysis

Short Term Liabilities: OPGN's short term assets ($29.8M) exceed its short term liabilities ($19.2M).

Long Term Liabilities: OPGN's short term assets ($29.8M) exceed its long term liabilities ($9.8M).


Debt to Equity History and Analysis

Debt Level: OPGN has more cash than its total debt.

Reducing Debt: OPGN's debt to equity ratio has increased from 33.6% to 63.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OPGN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OPGN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.3% each year


Dividend

What is OpGen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OPGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OPGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OPGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OPGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OPGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Oliver Schacht (50 yo)

1.58yrs

Tenure

US$1,097,732

Compensation

Dr. Oliver Schacht, Ph D., serves as Director, President and Chief Executive Officer at OpGen, Inc. since April 1, 2020. He was the Member of Management Board at Curetis N.V. and served as its Chief Execut...


CEO Compensation Analysis

Compensation vs Market: Oliver's total compensation ($USD1.10M) is above average for companies of similar size in the US market ($USD553.25K).

Compensation vs Earnings: Insufficient data to compare Oliver's compensation with company performance.


Leadership Team

Experienced Management: OPGN's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

Experienced Board: OPGN's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OPGN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 73.2%.


Top Shareholders

Company Information

OpGen, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: OpGen, Inc.
  • Ticker: OPGN
  • Exchange: NasdaqCM
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$59.983m
  • Shares outstanding: 38.95m
  • Website: https://www.opgen.com

Number of Employees


Location

  • OpGen, Inc.
  • 9717 Key West Avenue
  • Suite 100
  • Rockville
  • Maryland
  • 20850
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 00:18
End of Day Share Price2021/11/29 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.